![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Shionogi’s Naldemedine Shines in Phase 3
Shionogi’s Naldemedine Shines in Phase 3
February 25, 2016
Japanese drugmaker Shionogi’s opioid-induced constipation candidate naldemedine met the primary endpoint in a Phase 3 trial.
Specifically, 47.6 percent of patients experienced an increase in the frequency of spontaneous bowel movements from baseline for at least nine of 12 weeks versus 34.6 percent of patients on placebo.
Tested in patients with chronic non-cancer pain, naldemedine also improved secondary endpoints.
Upcoming Events
-
21Oct